Five of our most advanced and high-potential clinical and preclinical assets are being progressed to their next inflection points.

  • Target
  • Chemistry and Lead Optimisation
  • Preclinical
  • Phase I
  • Phase II
BEN-8744 Ulcerative Colitis
Target: PDE10
BEN-28010 Glioblastoma Multiforme
Target: CHK1
BEN-34712 ALS
Target: RAR⍺β
Parkinson's disease
Target: Novel Target
Target: Novel Target
Chronic Kidney Disease
Target: Multiple Targets
Idiopathic Pulmonary Fibrosis
Target: Multiple targets
Oncology, neurology, immunology
Target: Multiple Targets

Regular re-evaluation of 10+ paused programmes and potential new pipeline entries